TICKERNERD
Menu
BMEABMEAHealthcare · Biotechnology

BMEA Stock Forecast: Biomea Fusion, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.74
+2.35% on the day

The 7 Wall Street analysts covering Biomea Fusion, Inc. hold a median 12-month price target of $7 — +302.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$125.8M
Ticker Nerd rank
52 / 100
Median analyst target
$7.00
Analysts covering
7
Revenue$0.0
Operating income−$12.8M
Net income−$8.3M
Free cash flow−$10.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.9%
1M
+34.9%
YTD
+40.3%
1Y
−12.1%
From 52W high
−34.8%
From 52W low
+81.8%
$0.96
$2.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BMEA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Biomea Fusion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
84
Size
73
Issuance
68
Revisions
66
Accruals
54
Momentum
36
Value
30
Volatility
27
Quality
18

Growth (84): Sales and profits are climbing, and climbing faster than before.

Quality (18): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BMEA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BMEA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26BMEAHigh $9.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
6 Buy0 Hold1 Sell
Low $4.00Median $7.00High $9.00

The green dot is the last close — the median target sits +302.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
5 May 2026CitizensInitiatesMarket Outperform$9.00
28 Apr 2026D. Boral CapitalMaintainsBuy$12
8 Apr 2026D. Boral CapitalMaintainsBuy—
27 Mar 2026CitigroupMaintainsBuy—
25 Mar 2026D. Boral CapitalMaintainsBuy—
13 Jan 2026D. Boral CapitalMaintainsBuy—
10 Nov 2025CitigroupMaintainsBuy—
5 Nov 2025D. Boral CapitalMaintainsBuy—
27 Oct 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
3 Oct 2025D. Boral CapitalMaintainsBuy—
28 Aug 2025JefferiesInitiatesBuy—
11 Aug 2025CitigroupMaintainsBuy—
6 Aug 2025D. Boral CapitalMaintainsBuy—
6 Aug 2025ScotiabankMaintainsSector Outperform—
21 July 2025D. Boral CapitalMaintainsBuy—
16 July 2025CitigroupMaintainsBuy—
24 June 2025D. Boral CapitalMaintainsBuy—
18 June 2025D. Boral CapitalMaintainsBuy—
13 June 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BMEA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BMEA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Biomea Fusion, Inc. returned −12.1% against +17.5% for the S&P 500, dividends included.

BMEA vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Oct 25Jan 26Apr 26Jul 26BMEAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BMEA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Biomea Fusion, Inc. (BMEA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.5×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
10.4×

Cheaper than 9% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−164.1%

Higher than 9% of US stocks

Return on assets
−63.5%

Higher than 6% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Biomea Fusion, Inc. (BMEA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Biomea Fusion, Inc. has a market value of $125.8M and an enterprise value of $92.2M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$32.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$47.2M.

  • Shares outstanding: 72.5M.

  • Trailing P/E: −1.5×; forward P/E: −1.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Biomea Fusion, Inc. employs 37 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

BMEA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
BMEABiomea Fusion, Inc.$125.8M
52
TLSATiziana Life Sciences Ltd. (Bermuda)$123.2M
23
MISTMilestone Pharmaceuticals, Inc.$122.0M
16
HURATuHURA Biosciences, Inc.$124.5M
19
OKUROnKure Therapeutics, Inc.$125.2M
52
VTVTvTv Therapeutics, Inc.$125.9M
77
CBUSCibus, Inc.$119.6M
36

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Biomea Fusion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BMEA news & analysis

After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright

Zacks Investment Research · 4 Sept 2026positive

Zacks Investment Research reported that Biomea Fusion, Inc. (BMEA) reached a key level of support, and its 50-day simple moving average crossed above its 200-day simple moving average—a technical pattern known as a "golden cross." The item frames this as indicating a bright technical outlook for the stock.

Why it matters — BMEA watchers would care because the golden cross and support level are technical signals that reflect a shift in the stock's market momentum and trend direction.

Biomea Fusion to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Biomea Fusion announced that members of its management team will participate in Citi's 2026 Biopharma Back to School Conference, holding one-on-one investor meetings on September 10, 2026, in New York, New York.

Why it matters — This is an opportunity for the company's management to engage directly with investors at a major biopharma conference, which could raise the company's visibility.

Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion

Benzinga · 24 Aug 2026positive

Biomea Fusion's stock surged on Monday after the company completed enrollment in a Phase II diabetes trial, an operational milestone for its lead metabolic drug program.

Why it matters — A BMEA watcher would care because completing enrollment in the lead drug's Phase II trial represents a key step forward for the company's metabolic pipeline.

Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes

GlobeNewsWire · 24 Aug 2026positive

Biomea Fusion announced that enrollment has been completed in COVALENT-211, its randomized, double-blinded, placebo-controlled Phase II clinical trial evaluating icovamenib in patients with insulin-deficient type 2 diabetes who remain inadequately controlled on standard-of-care antihyperglycemic therapies.

Why it matters — Completing enrollment in the COVALENT-211 Phase II trial moves the icovamenib development program for insulin-deficient type 2 diabetes into the next clinical stage, a key milestone for Biomea Fusion shareholders to monitor.

Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?

Invezz · 24 Aug 2026positive

A Citi analyst issued a $7 price target for Biomea Fusion, implying about 410% upside from the price used in the call, as part of a note highlighting two biotech stocks with large potential gains. The report also noted that such forecasts carry significant risk.

Why it matters — The Citi price target highlights a positive analyst view on Biomea Fusion's potential, giving investors a notable valuation benchmark for the stock.

FAQ

Frequently asked questions about BMEA stock

What is the BMEA stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Biomea Fusion, Inc. have a median 12-month price target of $7, with estimates ranging from $4 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BMEA stock a buy right now?

Of the 7 analysts covering Biomea Fusion, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biomea Fusion, Inc. 52 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BMEA?

As at 12 Sept 2026, Biomea Fusion, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (84 of 100).

Will BMEA stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +302.3% from the last close, and Ticker Nerd's factor model ranks Biomea Fusion, Inc. 52 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BMEA stock forecast for 2030?

No analyst covering Biomea Fusion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BMEA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $9 over the next 12 months.

How has BMEA stock performed over the past year?

Biomea Fusion, Inc. returned -12.1% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Biomea Fusion, Inc. do?

Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases.

What is the latest news on BMEA?

The most recent item we track (Zacks Investment Research, 4 Sept 2026): "After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright". Zacks Investment Research reported that Biomea Fusion, Inc. (BMEA) reached a key level of support, and its 50-day simple moving average crossed above its 200-day simple moving average—a technical pattern known as a "golden cross." The item frames this as indicating a bright technical outlook for the stock.

Company

About Biomea Fusion, Inc.

Biomea Fusion Inc. is a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes, obesity, and other metabolic diseases. Its current pipeline centers on icovamenib, a menin inhibitor being studied across multiple diabetes programs, and BMF-650, an oral GLP-1 receptor agonist in development for obesity. The company’s work is built around covalent chemistry and precision drug design, with an emphasis on therapies intended to address biologically defined patient groups. Biomea Fusion Inc. also explores applications in genetically defined cancers through its broader small-molecule research platform. Headquartered in San Carlos, California, Biomea Fusion Inc. plays a role in the biopharmaceutical market as a developer of investigational treatments aimed at challenging endocrine and metabolic conditions.

CEO Dr. Michael J. M. Hitchcock Ph.D. · 37 employees · United States · https://biomeafusion.com